Free Newsletter
Deal adds drug analysis to Millipore offerings
Millipore is establishing a beachhead extending its reach into Europe, the home turf of competitor Sartorius Stedim Biotech, through the acquisition of U.K.-based BioAnaLab, a specialist service provider for biologic drug and vaccine analysis.
The deal lets Millipore further establish its biopharmaceutical services business and fortify its status as an outsource partner, according to a company announcement. BioAnaLab brings GMP support testing capabilities and its customer base to the deal. The Oxford company was spun out of the University of Oxford in 2002.
For its part, Goettingen, Germany-based Sartorius Stedim announced in July that it is partnering with cell culture media specialist SAFC Biosciences to provide fluid management and liquid/powder system solutions for upstream and downstream processing. The deal is expected to further the German company's offerings of single-use bioprocess technology.
- see the Millipore announcement
- here's the Sartorius Stedim release
Related Articles:
Millipore expands in Massachusetts
Disposable bioreactor boasts impeller stirring
Millipore, Astellas ink contract
Millipore streamlines, closes plants
Millipore expands in Missouri
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities


SHARE
WITH: